Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-G-CSF adjuvant for hepatitis B vaccine nonresponse in hemodialysis patients
IRCT20090701002113N4Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pegfilgrastim and Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Antibody to hepatitis B surface antigen, Response rates to vaccine and 1 more. Started Dec 2025; status: completed.
02
Drugs
pegfilgrastimHepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on IRCT20090701002113N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090701002113N4.